BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2474382)

  • 21. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma.
    Coiffier B; Gisselbrecht C; Herbrecht R; Tilly H; Bosly A; Brousse N
    J Clin Oncol; 1989 Aug; 7(8):1018-26. PubMed ID: 2474057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma.
    Bosly A; Lepage E; Coiffier B; Fillet G; Herbrecht R; Divine M; Dupriez B; Nouvel C; Deconninck E; Tilly H; Bordessoule D; Gaulard P; Gisselbrecht C;
    Hematol J; 2001; 2(4):279-85. PubMed ID: 11920261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. French-Italian Cooperative Group.
    Gisselbrecht C; Oksenhendler E; Tirelli U; Lepage E; Gabarre J; Farcet JP; Gastaldi R; Coiffier B; Thyss A; Raphael M
    Am J Med; 1993 Aug; 95(2):188-96. PubMed ID: 7689296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclic alternating chemotherapy of high-grade malignant non-Hodgkin lymphomas with VIM-Bleo and CHOP.
    Steinke B; Bross K; Reinold HM; Heim ME; Schalk KP; Heidemann E; Josten K; Arnold H; Manegold C; Hoffman I
    Eur J Cancer; 1992; 28(1):100-4. PubMed ID: 1373634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.
    Haioun C; Lepage E; Gisselbrecht C; Salles G; Coiffier B; Brice P; Bosly A; Morel P; Nouvel C; Tilly H; Lederlin P; Sebban C; Brière J; Gaulard P; Reyes F
    J Clin Oncol; 2000 Aug; 18(16):3025-30. PubMed ID: 10944137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequential combination chemotherapy (CABOPP/VIM) for the treatment of high-grade malignant non-Hodgkin lymphoma.
    Nowrousian MR; Meier CR; Schoetensack B; Anders C; Höffken K; Osieka R; Schmidt CG
    Acta Oncol; 1989; 28(4):495-500. PubMed ID: 2477048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte).
    Lepage E; Gisselbrecht C; Haioun C; Sebban C; Tilly H; Bosly A; Morel P; Herbrecht R; Reyes F; Coiffier B
    Ann Oncol; 1993 Sep; 4(8):651-6. PubMed ID: 7694634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma.
    McMaster ML; Johnson DH; Greer JP; Wolff SN; Hildreth CR; Greco FA; Hainsworth JD
    Cancer; 1991 Mar; 67(6):1487-92. PubMed ID: 1705861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Failure of IMVP-16 as second-line treatment for relapsed or refractory high grade non-Hodgkin's lymphoma.
    De Lord C; Newland AC; Linch DC; Vaughan Hudson B; Vaughan Hudson G
    Hematol Oncol; 1992; 10(2):81-6. PubMed ID: 1592365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease and non-Hodgkin's lymphoma. The Swedish Lymphoma Study Group.
    Enblad G; Glimelius B; Hagberg H; Lindemalm C
    Acta Oncol; 1990; 29(3):297-301. PubMed ID: 2363941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A six-drug regimen (MAPECO) for intermediate or high-grade non-Hodgkin's lymphoma.
    Pendleton N; Green JA
    Acta Oncol; 1994; 33(5):513-8. PubMed ID: 7917364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
    Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
    J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alternating six-drug combination chemotherapy induction for intermediate and high-grade non-Hodgkin's lymphoma.
    Green JA; Errington RD; Nash JR; Coe MA; Warenius HM
    Cancer Chemother Pharmacol; 1989; 24(5):326-8. PubMed ID: 2758562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Feasibility of high-dose chemotherapy without stem cell support as a first-line treatment for non-Hodgkin's aggressive lymphoma: a pilot study.
    Inoue R; Natazuka T; Shimoyama M; Tamekane A; Kajimoto Y; Iwata N; Matsuoka H; Chihara K; Matsui T
    Leuk Lymphoma; 2000 Jan; 36(3-4):315-21. PubMed ID: 10674903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Stamatoullas A; Fruchart C; Bastit D; Boulet D; Moncondult M; Piguet H; Tilly H
    Cancer; 1996 Jun; 77(11):2302-7. PubMed ID: 8635099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Salvage chemotherapy with a combination of VP-16, ifosfamide, procarbazine, prednisolone, bleomycin and methotrexate (VIPP-BM) for refractory malignant lymphoma].
    Ohnishi K; Hotta T; Murate T; Inoue C; Ichikawa A; Ninomiya N; Goto S; Tsushita K; Utsumi M; Nagura E
    Rinsho Ketsueki; 1989 Mar; 30(3):289-96. PubMed ID: 2475652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype.
    Marotta G; Bigazzi C; Bocchia M; Forconi F; Lauria F
    Haematologica; 1998 Sep; 83(9):853-4. PubMed ID: 9825583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensive treatment of stage III-IV aggressive malignant lymphomas (protocol TPL-84).
    Colombat P; Guilhot F; Bordesoule D; Renou P; Benz-Lemoine E; Fouillard L; Drouet M; Tanzer J; Lamagnere JP
    Haematologica; 1991; 76(6):479-84. PubMed ID: 1726492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [VEPA and ML-Y1 regimen for elderly non-Hodgkin's lymphoma].
    Tanabe J; Kanamori H; Matsuzaki M; Motomura S; Mohri H; Okubo T; Maruta A; Kodama F
    Nihon Ronen Igakkai Zasshi; 1994 Feb; 31(2):135-41. PubMed ID: 7517465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.